Skip to main content
Login
Contact
Subscribe
Search form
Search
The Borger News-Herald
Home
Forms
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Calendar
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Ardelyx Inc
(NQ:
ARDX
)
6.670
USD
+0.010 (+0.15%)
Official Closing Price
Updated: 5:57 PM EST, Mar 5, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Ardelyx Inc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ - New Innovative Treatment for Irritable Bowel Syndrome with Constipation
March 01, 2021
From
GlobeNewswire News Releases
Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 17, 2021
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today...
From
PR Newswire
12 Health Care Stocks Moving In Friday's After-Market Session
January 08, 2021
Gainers Aileron Therapeutics (NASDAQ:ALRN) stock moved upwards by 33.25% to $1.8 during Friday's after-market session. This ...
Tags
General
AZRX
BNGO
From
Benzinga
Thinking about buying stock in Capricor Therapeutics, Cardtronics, Clearside Biomedical, Ardelyx, or FuelCell Energy?
January 08, 2021
InvestorsObserver issues critical PriceWatch Alerts for CAPR, CATM, CLSD, ARDX, and FCEL.
From
PR Newswire
Benzinga's Top Upgrades, Downgrades For January 6, 2021
January 06, 2021
Upgrades For Regenxbio Inc (NASDAQ:RGNX), Raymond James upgraded the previous rating of Outperform to Strong Buy. For ...
Tags
Market News
BZI/Ratings
COR
From
Benzinga
Analysts Expect LABU To Hit $150
December 31, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
Top Buys by Directors: Mott's $1M Bet on ARDX
December 29, 2020
The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company...
Tags
Stocks
From
Market News Video
Noteworthy Thursday Option Activity: ARDX, IIPR, MGNX
December 17, 2020
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ardelyx Inc (ARDX), where a total of 3,858 contracts have traded so far, representing...
Tags
Stocks
From
Market News Video
72 Biggest Movers From Friday
December 14, 2020
Gainers AbCellera Biologics Inc. (NASDAQ: ABCL) shares jumped 194.5% to close at $58.90 after the company priced its IPO at $20 ...
Tags
Movers From Friday
MKGI
PCVX
From
Benzinga
Notable Insider Buys Of The Past Week: Avis Budget, Biotech IPOs, And More
December 12, 2020
As the year winds down, plenty of insiders have purchased shares despite some market volatility and economic uncertainty. Here are some of the most noteworthy insider purchases that were reported in...
Tags
Stocks / Equities
From
Blogs - TalkMarkets
Notable Insider Buys Of the Past Week: Avis Budget, Biotech IPOs And More
December 12, 2020
Insider buying can be an encouraging signal for potential investors when markets face uncertainty. This past week, some insiders ...
Tags
Multiplan
Avnet
Coty
From
Benzinga
60 Stocks Moving In Friday's Mid-Day Session
December 11, 2020
Gainers TPG Pace Beneficial Finance Corp. (NYSE: TPGY) shares jumped 111.5% to $23.48 on a merger deal with EV charging company ...
Tags
XXII
Mid/Day Movers
JOUT
From
Benzinga
Friday 12/11 Insider Buying Report: ARDX, BCAT
December 11, 2020
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
Tags
Stocks
From
Market News Video
Thinking about buying stock in Walt Disney, vTv Therapeutics, 22nd Century Group, Lexicon Pharmaceuticals, or Ardelyx?
December 11, 2020
InvestorsObserver issues critical PriceWatch Alerts for DIS, VTVT, XXII, LXRX, and ARDX.
From
PR Newswire
12 Healthcare Stocks Moving In Friday's Pre-Market Session
December 11, 2020
Gainers vTv Therapeutics (NASDAQ:VTVT) stock moved upwards by 120.09% to $4.82 during Friday's pre-market session. ...
Tags
Top Gainers
Pre/Market Outlook
IMMP
From
Benzinga
Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 23, 2020
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today...
From
PR Newswire
Ardelyx to Present at the Jefferies Virtual London Healthcare Conference
November 10, 2020
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today...
From
PR Newswire
Ardelyx to Webcast Virtual Analyst Day
November 06, 2020
--Featuring a panel of distinguished guest speakers--
From
PR Newswire
Analysts Expect 56% Upside For XBI
November 06, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights
November 05, 2020
Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021
From
PR Newswire
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
October 22, 2020
--Data presented across five posters continue to support the foundational role tenapanorcould play in the treatment of hyperphosphatemia--
From
PR Newswire
Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020
October 22, 2020
--Campaign highlights Ardelyx commitment to advance the science of phosphate absorption to address significant unmet needs in the current treatment of hyperphosphatemia--
From
PR Newswire
Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
October 12, 2020
--Comprehensive datasets demonstrate tenapanor's ability to control serum phosphorous in patients with chronic kidney disease (CKD) on dialysis--
From
PR Newswire
TUSA's Underlying Holdings Could Mean 10% Gain Potential
October 06, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
First Week of November 20th Options Trading For Ardelyx (ARDX)
September 18, 2020
Investors in Ardelyx Inc (ARDX) saw new options begin trading this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX options chain...
Tags
Stocks
From
Market News Video
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
September 15, 2020
NDA Supported by Data from Expansive Clinical Development Program Demonstrating Tenapanor's use as Foundational Therapy
From
PR Newswire
Ardelyx to Participate in Three Upcoming Investor Conferences in September
September 08, 2020
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that...
From
PR Newswire
How The Parts Add Up: LABU Targets $79
September 03, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
August 06, 2020
Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney...
From
PR Newswire
Analysts See 45% Gains Ahead For XBI
August 03, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.